Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Breden, Felix ^a   Lepik, Christa ^a,c   Longo, Nancy S ^b,d   Montero, Marinieve ^a,e   Lipsky, Peter E ^b,f   Scott, Jamie K ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; VIRUS ANTIBODY; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; GENETIC SELECTION; GERM LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PERSISTENT INFECTION; SEQUENCE DATABASE; SOMATIC MUTATION; VIRUS INFECTION; ACUTE DISEASE; CHRONIC DISEASE; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MUTATION;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS 1;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; AUTOIMMUNE DISEASES; CHRONIC DISEASE; COMPLEMENTARITY DETERMINING REGIONS; EPITOPES; GENE EXPRESSION REGULATION; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MUTATION;

EID: 79953316880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016857     Document Type: Article

References (63)

1. Tonegawa S, (1983) Somatic generation of antibody diversity. Nature 302: 575-581.
2. Market E, Papavasiliou FN, (2003) V(D)J recombination and the evolution of the adaptive immune system. PLoS Biol 1: E16.
3. Wu TT, Johnson G, Kabat EA, (1993) Length distribution of CDRH3 in antibodies. Proteins 16: 1-7.
4. Schief WR, Ban YE, Stamatatos L, (2009) Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 4: 431-440.
5. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
6. Binley JA, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Journal of Virology 78: 13232-13252.
7. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
8. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805.
9. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
10. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337-7348.
11. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, et al. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84: 1631-1636.
12. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149.
13. Kunert R, Ruker F, Katinger H, (1998) Molecular characterization of five neutralizing anti-HIV type 1 antibodies: Identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Research and Human Retroviruses 14: 1115-1128.
14. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, et al. (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155-1159.
15. Zwick MB, Parren PWHI, Saphire EO, Church S, Wang M, et al. (2003) Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of Human Immunodeficiency Virus Type 1 gp120 10.1128/JVI.77.10.5863-5876.2003. J Virol 77: 5863-5876.
16. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78: 10724-10737.
17. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA, (2004) Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12: 193-204.
18. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163-173.
19. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
20. Nabel GJ, (2005) Immunology. Close to the edge: neutralizing the HIV-1 envelope. Science 308: 1878-1879.
21. Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, et al. (2010) Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 5: e10254.
22. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
23. Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-Human Immunodeficiency Virus Type 1 antibody 2F5 10.1128/JVI.78.6.3155-3161.2004. J Virol 78: 3155-3161.
24. Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, et al. (2010) Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol 84: 4136-4147.
25. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR, (2010) Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 107: 1529-1534.
26. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. Journal of Immunology 178: 4424-4435.
27. Johnson G, Wu TT, (1998) Preferred CDRH3 lengths for antibodies with defined specificities. Int Immunol 10: 1801-1805.
28. Collis AVJ, Brouwer AP, Martin ACR, (2003) Analysis of the antigen combining site: Correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. Journal of Molecular Biology 325: 337-354.
29. Baxendale HE, Johnson M, Stephens RC, Yuste J, Klein N, et al. (2008) Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin Exp Immunol 151: 51-60.
30. Notkins AL, (2004) Polyreactivity of antibody molecules. Trends in Immunology 25: 174-179.
31. Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, et al. (2006) Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 203: 2255-2261.
32. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, et al. (2007) Autoreactivity in human IgG+ memory B cells. Immunity 26: 205-213.
33. Song H, Cerny J, (2003) Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen. J Exp Med 198: 1923-1935.
34. Phan TG, Gardam S, Basten A, Brink R, (2005) Altered migration, recruitment, and somatic hypermutation in the early response of marginal zone B cells to T cell-dependent antigen. J Immunol 174: 4567-4578.
35. Baumgarth N, (2011) The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 11: 34-46.
36. Tangye SG, Good KL, (2007) Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol 179: 13-19.
37. Berberian L, Goodglick L, Kipps TJ, Braun J, (1993) Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 261: 1588-1591.
38. David D, Demaison C, Bani L, Zouali M, Theze J, (1995) Selective variations in vivo of VH3 and VH1 gene family expression in peripheral B cell IgM, IgD and IgG during HIV infection. Eur J Immunol 25: 1524-1528.
39. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377.
40. Matsuda F, Ishii K, Bourvagnet P, Kuma K, Hayashida H, et al. (1998) The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med 188: 2151-2162.
41. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, et al. (2009) Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83: 662-672.
42. CHAVI CfH-AVI (2006) https://chavi.org/modules/chavi_mem_pols/index.php?id=1.
43. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458: 636-640.
44. Wisnewski A, Cavacini L, Posner M, (1996) Human antibody variable region gene usage in HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 11: 31-38.
45. Scamurra RW, Miller DJ, Dahl L, Abrahamsen M, Kapur V, et al. (2000) Impact of HIV-1 infection on VH3 gene repertoire of naive human B cells. J Immunol 164: 5482-5491.
46. Gorny MK, Wang X, Jiang X, Williams C, Volsky B, et al. (2008) Immunoglobulin gene usage by neutralizing human anti-V3 HIV-1 monoclonal antibodies derived from clade B and non-B HIV-1 infected individuals. AIDS Research and Human Retroviruses 24: 46-46.
47. Muller S, Kohler H, (1997) B cell superantigens in HIV-1 infection. Int Rev Immunol 14: 339-349.
48. Viau M, Veas F, Zouali M, (2007) Direct impact of inactivated HIV-1 virions on B lymphocyte subsets. Molecular Immunology 44: 2124-2134.
49. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, et al. (2004) Structural basis of tyrosine sulfation and V-H-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proceedings of the National Academy of Sciences of the United States of America 101: 2706-2711.
50. Throsby M, van den Brink E, Jongeneelen M, Poon LLM, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3: e3942.
51. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
52. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105: 5986-5991.
53. de Wildt RM, van Venrooij WJ, Winter G, Hoet RM, Tomlinson IM, (1999) Somatic insertions and deletions shape the human antibody repertoire. J Mol Biol 294: 701-710.
54. Zouali M, (2008) Receptor editing and receptor revision in rheumatic autoimmune diseases. Trends in Immunology 29: 103-109.
55. Klonowski KD, Monestier M, (2001) Ig heavy-chain gene revision: leaping towards autoimmunity. Trends in Immunology 22: 400-405.
56. Walker LM, Burton DR, (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22: 358-366.
57. Ofek G, Guenaga FJ, Schief WR, Skinner J, Baker D, et al. (2010) Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 107: 17880-17887.
58. Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, et al. (2010) Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18: 1116-1126.
59. Wang TT, Tan GS, Hai R, Pica N, Petersen E, et al. (2010) Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6: e1000796.
60. Souto-Carneiro MM, Longo NS, Russ DE, Sun HW, Lipsky PE, (2004) Characterization of the human Ig heavy chain antigen binding complementarity determining region 3 using a newly developed software algorithm, JOINSOLVER. J Immunol 172: 6790-6802.
61. Ditzel HJ, Parren PW, Binley JM, Sodroski J, Moore JP, et al. (1997) Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries. J Mol Biol 267: 684-695.
62. Lefranc MP, (2005) IMGT, the international ImMunoGeneTics information system: a standardized approach for immunogenetics and immunoinformatics. Immunome Res 1: 3.
63. Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, et al. (2003) Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 334: 733-749.